Recently the results of a study that was carried out over a period of almost two years was released by the National Institute of Cancerologia in Mexico City. The study involved following thirty patients who were suffering from the asbestos related cancer, mesothelioma, and eveluating the success of combination drug therapy.

The combination drug therapy that was being looked at as part of the study was treatment with the two drugs liposomal doxorubicin and cisplatin, which it was hoped would extend the survival times of patients. The thirty patients were studied between September 2007 and April of this year.

It was found that the combination drug therpay provided a success rate of twenty five percent compared to a success rate of twenty percent with a single drug treatment. Researchers are hoping that the combination therapy will provide sufferers of this disease with increased stability and a longer survivial period.

One industry expert, Dr. H. Ian Robins, a University of Wisconsin Professor and oncologist, has claimed that the future of mesothelioma treatment may lie in combination drug therapies such as this one rather than in single drug treatments, asn the combination ones appear to be more effective.

Be Sociable, Share!